MANKIND Share Price Performance
₹0
-2415.40 (-100.00%)
Price ₹0
Fair Value₹2,506.53
Share Pricen/a
Mankind Pharma Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
MANKIND Community Narratives
AN
Fair Value
·Fair Value ₹2.51k 9.9% undervalued intrinsic discount
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value
·Fair Value ₹3.09k 26.8% undervalued intrinsic discount
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹1.99k 13.5% overvalued intrinsic discount
Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
Key Takeaways Strong specialty biologics portfolio, innovative pipeline, and rapid execution position the company for accelerated margin and earnings growth ahead of consensus expectations. Expanding distribution, premium consumer brands, and robust R&D create a structural edge to capitalize on rising healthcare demand and chronic disease prevalence.Read more
AN
₹3.09k
26.8% undervalued intrinsic discount
Fair Value
Revenue
14.35% p.a.
Profit Margin
21.56%
Future PE
40.44x
Price in 2029
₹4.38k
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
Key Takeaways Strong focus on high-margin chronic therapies, consumer health growth, and specialty drugs positions the company for sustained revenue expansion and improved earnings quality. Enhanced operational efficiency, R&D investment, and expanding modern trade presence support scalable profitability and mitigate future margin pressures.Read more
AN
₹2.51k
9.9% undervalued intrinsic discount
Fair Value
Revenue
11.39% p.a.
Profit Margin
18.4%
Future PE
41.64x
Price in 2029
₹3.56k
Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects
Key Takeaways Reliance on low-margin domestic generics and regulatory shifts risks eroding margins and threatens long-term profit sustainability. Limited global presence and lag in digital healthcare adoption expose the company to heightened market and competitive vulnerabilities.Read more
AN
₹1.99k
13.5% overvalued intrinsic discount
Fair Value
Revenue
6.71% p.a.
Profit Margin
18.55%
Future PE
40.27x
Price in 2029
₹3.05k
Trending Discussion
Recently Updated Narratives
AN
MANKIND: Subsidiary Closure Decision Will Support Future Re Rating Potential
Fair Value: ₹3.09k 26.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MANKIND: Upcoming Results And Solid Margins Will Support Further Upside
Fair Value: ₹2.51k 9.9% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
MANKIND: Fair Value Outlook Will Reflect Lower Growth And Higher Margins
Fair Value: ₹1.99k 13.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mankind Pharma Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 43.21
- 70.25%
- 12.82%
- 53.9%
About MANKIND
- Founded
- 1991
- Employees
- 19620
- CEO
- WebsiteView website
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
Recent MANKIND News & Updates
MANKIND: Upcoming Results And Solid Margins Will Support Further Upside
Analysts have cut their price target on Mankind Pharma by ₹30 to reflect slightly lower assumptions for revenue growth, profit margins and future P/E multiples, resulting in a modest reset in fair value expectations. What's in the News A board meeting is scheduled on Feb 3, 2026 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).